Target Name: RNF133
NCBI ID: G168433
Review Report on RNF133 Target / Biomarker Content of Review Report on RNF133 Target / Biomarker
RNF133
Other Name(s): RN133_HUMAN | Ring finger protein 133 | MGC27072 | RING-type E3 ubiquitin transferase RNF133 | ring finger protein 133 | RING finger protein 133 | E3 ubiquitin-protein ligase RNF133 | OTTHUMP00000211453

Unlocking the Potential of RNF133: A novel Drug Target and Biomarker

Rare nuclear factor 133 (RNF133) is a non-coding RNA molecule that plays a crucial role in various cellular processes. It is a protein-coding gene that has not yet been associated with any diseases. However, its functions and potential implications as a drug target or biomarker are under investigation. In this article, we will explore the potential of RNF133 as a drug target and biomarker.

Drug Target

RNF133 has been identified as a potential drug target due to its unique structure and its involvement in various cellular processes. It is a small molecule that can interact with various nuclear factors, including activating transcription factor 1 (ATF1), which plays a crucial role in cell growth and survival.

ATF1 is a transcription factor that regulates gene expression by binding to specific DNA sequences. It has been implicated in various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. Therefore, targeting ATF1 with small molecules that can modulate its activity could be a promising strategy for developing new treatments.

RNF133 has been shown to interact with ATF1 and can modulate its activity. Several studies have demonstrated that RNF133 can inhibit the activity of ATF1 and enhance the activity of negative transcription factors (NTRs), which are known to play a role in gene repression.

In addition, RNF133 has been shown to regulate the expression of genes involved in cell adhesion, migration, and invasion, which are critical processes in cancer progression. Therefore, targeting RNF133 with small molecules that can modulate its activity could be a promising strategy for developing new treatments for various types of cancer.

Biomarker

RNF133 has also been identified as a potential biomarker for various diseases. Its functions and potential implications as a biomarker are under investigation.

One of the promising aspects of RNF133 is its potential to serve as a biomarker for cancer. Cancer is a leading cause of death worldwide, and early detection is crucial for effective treatment. RNF133 has been shown to be downregulated in various types of cancer, including breast, ovarian, and prostate cancers. Therefore, targeting RNF133 with small molecules that can modulate its activity could be a promising strategy for developing new treatments for cancer.

Another promising aspect of RNF133 is its potential to serve as a biomarker for neurodegenerative diseases. Neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease, are progressive neurological disorders that are characterized by the progressive loss of brain cells. RNF133 has been shown to be involved in the regulation of neurogenesis and has been implicated in the development and progression of neurodegenerative diseases. Therefore, targeting RNF133 with small molecules that can modulate its activity could be a promising strategy for developing new treatments for neurodegenerative diseases.

Conclusion

In conclusion, RNF133 is a novel drug target and biomarker that has the potential to revolutionize our understanding of various diseases. Its unique structure and its involvement in various cellular processes make it an attractive target for small molecules that can modulate its activity. Further research is needed to fully understand the functions and potential implications of RNF133 as a drug target and biomarker.

Protein Name: Ring Finger Protein 133

Functions: Has E3 ubiquitin-protein ligase activity

The "RNF133 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about RNF133 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

RNF135 | RNF138 | RNF138P1 | RNF139 | RNF139-DT | RNF14 | RNF141 | RNF144A | RNF144B | RNF145 | RNF146 | RNF148 | RNF149 | RNF150 | RNF151 | RNF152 | RNF157 | RNF157-AS1 | RNF165 | RNF166 | RNF167 | RNF168 | RNF169 | RNF17 | RNF170 | RNF175 | RNF180 | RNF181 | RNF182 | RNF183 | RNF185 | RNF186 | RNF187 | RNF19A | RNF19B | RNF2 | RNF20 | RNF207 | RNF208 | RNF212 | RNF212B | RNF213 | RNF213-AS1 | RNF214 | RNF215 | RNF216 | RNF216-IT1 | RNF216P1 | RNF217 | RNF217-AS1 | RNF220 | RNF222 | RNF224 | RNF225 | RNF227 | RNF24 | RNF25 | RNF26 | RNF31 | RNF32 | RNF32-DT | RNF34 | RNF38 | RNF39 | RNF4 | RNF40 | RNF41 | RNF43 | RNF44 | RNF5 | RNF5P1 | RNF6 | RNF7 | RNF7P1 | RNF8 | RNFT1 | RNFT2 | RNGTT | RNH1 | RNLS | RNMT | RNPC3 | RNPC3-DT | RNPEP | RNPEPL1 | RNPS1 | RNPS1P1 | RNR1 | RNR2 | RNU1-1 | RNU1-100P | RNU1-108P | RNU1-11P | RNU1-134P | RNU1-18P | RNU1-3 | RNU1-31P | RNU1-32P | RNU1-36P | RNU1-38P